A few previous studies have examined the efficacy of PARP inhibition in VHL-deficient RCC cells (29) and in hereditary cancer syndromes (30) using olaparib and BMN-673 (talazoparib). This evidence concerns the gene VHL and Inherited cancer-predisposing syndrome.